BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 8, 2006
View Archived Issues
Gabapentin effects differ in studies of alcohol withdrawal and cocaine dependence
Read More
Seikagaku terminates option and license agreements
Read More
Shire files SPD-476 in Europe for ulcerative colitis
Read More
Second pivotal phase III trial begins for Xerecept
Read More
Arrow advances lead hepatitis C compound into full preclinical development
Read More
Phase I study of EVT-101 completes single ascending dose component
Read More
ISIS-301012 begins phase II for familial hypercholesterolemia
Read More
CSA-54 shows potent virucidal activity in in vitro tests against HIV
Read More
Phase II study to investigate CA4P with chemoradiotherapy in NSCLC
Read More
Calando and NCI collaborate to develop RNAi therapeutics
Read More
Canadian clearance for phase Ib/II trial of CTCE-9908 in advanced cancers
Read More
Research collaboration to evaluate nasal delivery for Alzheimer's disease
Read More
Bicifadine studied in new phase II trial for diabetic peripheral neuropathy
Read More
Resistentia gets Swedish clearance for phase I study of RP-01
Read More
Antiangiogenic effects of TSRATS-4
Read More
Small interfering RNAs prevent herpes simplex virus-2 infection in vivo
Read More
New antiangiogenic and antitumor DNA vaccine targets angiostatin receptor
Read More
Peramivir a possible alternative to oseltamivir in treating influenza
Read More
EXEL-2880: preclinical antitumor and antiangiogenic activity
Read More
Eisai looks back on productive quarter
Read More
CHMP recommends approval of Exelon for Parkinson's disease dementia
Read More
Telbivudine submitted for European approval
Read More
Maribavir receives fast track designation for prevention of CMV infection
Read More
Recent patents impart novel therapeutic agents for respiratory disorders
Read More
Recent patents describe novel agents for cardiovascular disorders
Read More
Gardasil BLA granted priority review
Read More